Knight Therapeutics Company Executives
| GUD Stock | CAD 5.60 0.05 0.90% |
Knight Therapeutics employs about 725 people. The company is managed by 23 executives with a total tenure of roughly 87 years, averaging almost 3.0 years of service per executive, having 31.52 employees per reported executive. Analysis of Knight Therapeutics' management performance can provide insight into the firm performance.
| Jonathan Goodman CEO Chief Executive Officer, Director |
| James Gale Chairman Independent Chairman of the Board |
Knight |
Knight Therapeutics Management Team Effectiveness
Knight Therapeutics' management efficiency ratios could be used to measure how well Knight Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Knight Therapeutics Workforce Comparison
Knight Therapeutics is one of the top stocks in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 6,614. Knight Therapeutics retains roughly 725 in number of employees claiming about 11% of equities under Health Care industry.
Knight Therapeutics Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Knight Therapeutics Price Series Summation is a cross summation of Knight Therapeutics price series and its benchmark/peer.
Knight Therapeutics Notable Stakeholders
A Knight Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Knight Therapeutics often face trade-offs trying to please all of them. Knight Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Knight Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Jonathan Goodman | Chief Executive Officer, Director | Profile | |
| BA LLB | Executive Chairman | Profile | |
| James Gale | Independent Chairman of the Board | Profile | |
| Samira Sakhia | President, Chief Financial Officer, Director | Profile | |
| Leopoldo Bosano | VicePresident Operations | Profile | |
| Amal Khouri | Vice President - Business Development | Profile | |
| Arvind Utchanah | Chief Financial Officer | Profile | |
| Robert Lande | Independent Director | Profile | |
| Nancy Harrison | Independent Director | Profile | |
| Sylvie Tendler | Independent Director | Profile | |
| Meir Jakobsohn | Director | Profile | |
| Jody Engel | Senior Director - Business Development | Profile | |
| BA BA | Ex Chairman | Profile | |
| Monica Percario | Global Affairs | Profile | |
| Michael Tremblay | Independent Director | Profile | |
| Susan Emblem | Global Resources | Profile | |
| Stephani Saverio | Vice Development | Profile | |
| Henrique Dias | Global Marketing | Profile | |
| Jeff Martens | Global Commercial | Profile | |
| Janice Murray | Independent Director | Profile | |
| Nicolas Sujoy | Independent Director | Profile | |
| Daniela Marino | Global Compliance | Profile | |
| Melanie Groleau | Global Clinical | Profile |
About Knight Therapeutics Management Performance
The success or failure of an entity such as Knight Therapeutics often depends on how effective the management is. Knight Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Knight management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Knight management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Knight Therapeutics Inc. operates as a specialty pharmaceutical company in Canada and internationally. The company was incorporated in 2013 and is headquartered in Montreal, Canada. KNIGHT THERAPEUTICS operates under Drug ManufacturersSpecialty Generic classification in Canada and is traded on Toronto Stock Exchange.
Knight Therapeutics Workforce Analysis
Traditionally, organizations such as Knight Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Knight Therapeutics within its industry.Knight Therapeutics Manpower Efficiency
Return on Knight Therapeutics Manpower
| Revenue Per Employee | 452.7K | |
| Revenue Per Executive | 14.3M | |
| Net Loss Per Employee | 23.2K | |
| Net Loss Per Executive | 732K | |
| Working Capital Per Employee | 346.3K | |
| Working Capital Per Executive | 10.9M |
Other Information on Investing in Knight Stock
Knight Therapeutics financial ratios help investors to determine whether Knight Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Knight with respect to the benefits of owning Knight Therapeutics security.